Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02486718 · ClinicalTrials.gov registry record · Phase 3
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 1,280
- Enrollment target
- 20
- Study locations
NCT02486718: Active Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
NCT02486718 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 1,280 participants, above the 650-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02486718, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,280 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.
Primary Outcome
DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Atezolizumab
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Vinorelbine
Study Locations (20)
California
- California Cancer Associates for Research & Excellence, Inc. - Encinitas
- Compassionate Cancer Care Medical Group, Inc - Fountain Valley
- University of California Los Angeles - Los Angeles
- Kaiser Permanente - Vallejo
- Kaiser Permanente - Walnut Creek - Walnut Creek
New Jersey
- Hematology Oncology Associates of Northern New Jersey - Florham Park
- Saint Barnabas Medical Center - Livingston
- Valley Hospital - Paramus
- Overlook Medical Center - Summit
Florida
- Lynn Cancer Institute - West - Boca Raton
- University of Miami School of Medicine - Sylvester at Deerfield - Deerfield Beach
- SCRI Florida Cancer Specialists North - St. Petersburg
Illinois
- University of Illinois at Chicago - Chicago
- Illinois Cancer Care - Peoria
Arkansas
- Highlands Oncology Group - Fayetteville
Connecticut
- Eastern Connecticut Hematology and Oncology Associates - Norwich
Georgia
- Lewis Hall Singletary Oncology Center - Thomasville
Kentucky
- Norton Cancer Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,280 participants |
| Start Date | 2015-10-31 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 3 |
What the registry record for NCT02486718 still lists
NCT02486718 is an interventional study that assigns participants to a tested intervention. Its 1,280 participants enrollment target places it among the larger protocols in the corpus, above the 650-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% higher).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT02486718 names 20 study sites across 10 states, led by California, New Jersey, Florida.
Frequently Asked Questions
What is clinical trial NCT02486718 about?
NCT02486718 is a clinical study titled "Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]". This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC)...
What is the current status of trial NCT02486718?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,280 participants. The study started on 2015-10-31. Estimated completion is 2027-08-31.
What conditions does trial NCT02486718 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02486718?
The interventions under investigation include: Docetaxel (DRUG), Atezolizumab (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Vinorelbine (DRUG).
Who is sponsoring clinical trial NCT02486718?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02486718 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02486718's enrollment target sits among peer trials
1,280 15th of 454 higher than 440 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- NCT07207811 · 1,280 participants · Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI